$6.590
+2.934 (+44.52%)At close
BIAF News
BIAF Events
bioAffinity Advances CyPath Lung Test for Lung Cancer Recurrence Monitoring
bioAffinity Technologies is advancing the potential application of its CyPath Lung test for surveillance of lung cancer patients who have completed curative-intent treatment. Even when patients have no evidence of disease following surgery or radiation, published studies report recurrence rates of approximately 20% to 55% for non-small cell lung cancer. The American Society of Clinical Oncology recommends surveillance imaging every six months for two years following curative-intent treatment of stage I-III NSCLC, followed by annual low-dose CT to monitor for new primary lung cancers. The potential role of CyPath Lung in recurrence surveillance builds on the test's ability to analyze the lung microenvironment in real time. Drawing on three years of commercial experience, CyPath Lung has shown promising clinical performance in helping physicians stratify malignancy risk and guide patient management.
Selling Stockholders Plan to Sell 1.71M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.71M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
bioAffinity Technologies Inc Trading Halted, News Pending
bioAffinity Technologies Inc trading halted, news pending
bioAffinity Enters Agreement to Sell 8.46 Million Shares to Institutional Investor
bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock, together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock, in a private placement offering priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock and accompanying two warrants to be issued is $0.4727. The combined effective offering price for each pre-funded warrant and accompanying two warrants to be issued is $0.4657. The pre-funded warrants will have an exercise price of $0.007 per share of common stock and the warrants will have an exercise price of $0.4727 per share, will be exercisable following stockholder approval, and will expire five years from the date of issuance. The gross proceeds to the Company from the offering are estimated to be approximately $4M before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about August 14, subject to the satisfaction of customary closing conditions. WallachBeth Capital is acting as the sole placement agent in connection with the offering.
bioAffinity Publishes Clinical Review on CyPath Lung
bioAffinity Technologies announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon Downie, MD, PhD, that presents a practical clinical framework for incorporating CyPath Lung into pulmonary nodule evaluation and cancer surveillance. Titled "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath Lung Testing for Early Diagnosis of Lung Cancer," the paper examines the growing clinical challenge of evaluating pulmonary nodules as lung cancer screening expands, incidental findings increase, artificial intelligence identifies even more incidental nodules, and more patients require long-term surveillance following cancer treatment.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.